Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma

Victoria Foy; Mairead Mcnamara; Juan Valle; Angela Lamarca; Julien Edeline; Richard Hubner

doi:10.3390/curroncol30090628

Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma

Victoria Foy, Mairead Mcnamara, Juan Valle, Angela Lamarca, Julien Edeline, Richard Hubner

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

The treatment of advanced unresectable HCC (aHCC) remains a clinical challenge, with limited therapeutic options and poor prognosis. The results of IMbrave150 and HIMALAYA have changed the treatment paradigm for HCC and established immune checkpoint inhibition (ICI), either combined with anti-angiogenic therapy or dual ICI, as preferred first-line therapy for eligible patients with aHCC. Numerous other combination regimens involving ICI are under investigation with the aim of improving the tumour response and survival of patients with all stages of HCC. This review will explore the current evidence for ICI in patients with advanced HCC and discuss future directions, including the unmet clinical need for predictive biomarkers to facilitate patient selection, the effects of cirrhosis aetiology on response to ICI, and the safety of its use in patients with impaired liver function.

Original language	English
Pages (from-to)	8665-8685
Number of pages	21
Journal	Current Oncology
Volume	30
Issue number	9
DOIs	https://doi.org/10.3390/curroncol30090628
Publication status	Published - 21 Sept 2023

Keywords

ICI
HCC
PD-L1
PD-1
immunotherapy
biomarkers

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/curroncol30090628Licence: CC BY

Cite this

@article{7eb298cba4af4279ad70ddc69a42c189,

title = "Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma",

abstract = "The treatment of advanced unresectable HCC (aHCC) remains a clinical challenge, with limited therapeutic options and poor prognosis. The results of IMbrave150 and HIMALAYA have changed the treatment paradigm for HCC and established immune checkpoint inhibition (ICI), either combined with anti-angiogenic therapy or dual ICI, as preferred first-line therapy for eligible patients with aHCC. Numerous other combination regimens involving ICI are under investigation with the aim of improving the tumour response and survival of patients with all stages of HCC. This review will explore the current evidence for ICI in patients with advanced HCC and discuss future directions, including the unmet clinical need for predictive biomarkers to facilitate patient selection, the effects of cirrhosis aetiology on response to ICI, and the safety of its use in patients with impaired liver function.",

keywords = "ICI, HCC, PD-L1, PD-1, immunotherapy, biomarkers",

author = "Victoria Foy and Mairead Mcnamara and Juan Valle and Angela Lamarca and Julien Edeline and Richard Hubner",

year = "2023",

month = sep,

day = "21",

doi = "10.3390/curroncol30090628",

language = "English",

volume = "30",

pages = "8665--8685",

journal = "Current Oncology",

issn = "1198-0052",

publisher = "Multimed, Inc",

number = "9",

}

TY - JOUR

T1 - Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma

AU - Foy, Victoria

AU - Mcnamara, Mairead

AU - Valle, Juan

AU - Lamarca, Angela

AU - Edeline, Julien

AU - Hubner, Richard

PY - 2023/9/21

Y1 - 2023/9/21

N2 - The treatment of advanced unresectable HCC (aHCC) remains a clinical challenge, with limited therapeutic options and poor prognosis. The results of IMbrave150 and HIMALAYA have changed the treatment paradigm for HCC and established immune checkpoint inhibition (ICI), either combined with anti-angiogenic therapy or dual ICI, as preferred first-line therapy for eligible patients with aHCC. Numerous other combination regimens involving ICI are under investigation with the aim of improving the tumour response and survival of patients with all stages of HCC. This review will explore the current evidence for ICI in patients with advanced HCC and discuss future directions, including the unmet clinical need for predictive biomarkers to facilitate patient selection, the effects of cirrhosis aetiology on response to ICI, and the safety of its use in patients with impaired liver function.

AB - The treatment of advanced unresectable HCC (aHCC) remains a clinical challenge, with limited therapeutic options and poor prognosis. The results of IMbrave150 and HIMALAYA have changed the treatment paradigm for HCC and established immune checkpoint inhibition (ICI), either combined with anti-angiogenic therapy or dual ICI, as preferred first-line therapy for eligible patients with aHCC. Numerous other combination regimens involving ICI are under investigation with the aim of improving the tumour response and survival of patients with all stages of HCC. This review will explore the current evidence for ICI in patients with advanced HCC and discuss future directions, including the unmet clinical need for predictive biomarkers to facilitate patient selection, the effects of cirrhosis aetiology on response to ICI, and the safety of its use in patients with impaired liver function.

KW - ICI

KW - HCC

KW - PD-L1

KW - PD-1

KW - immunotherapy

KW - biomarkers

U2 - 10.3390/curroncol30090628

DO - 10.3390/curroncol30090628

M3 - Article

C2 - 37754543

SN - 1198-0052

VL - 30

SP - 8665

EP - 8685

JO - Current Oncology

JF - Current Oncology

IS - 9

ER -

Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this